Navigation Links
Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
Date:2/10/2009

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. Ri
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
2. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
3. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
4. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
5. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
6. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
7. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
8. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
9. The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML
10. ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
11. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the 38 th Annual Deutsche Bank ... on May 30, 2013, at 1:30 p.m. EDT. ... are invited to listen to the live discussion via ... it directly at http://www.media-server.com/m/p/f7bj3q84 . A recorded replay ...
(Date:5/20/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") today announced, ... (the "Announcement"), a firm intention to increase its offer ... to $12.50 per share in cash.  The increased offer ... due diligence.  The $1.00 per share net cash right ... to waive down the Acceptance Threshold for the increased ...
(Date:5/20/2013)... Sequent Medical, Inc. announced today that it ... family of WEB ® Aneurysm Embolization Devices, and ... in select neurovascular centers in Europe.  The SL family ... enable physicians to treat a broader range of aneurysms ... are made possible by further advancement of Sequent Medical,s ...
Breaking Medicine Technology:Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 2Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 3Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 4Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 5Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 6Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 7Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 8Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 9Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 10Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash 11Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2
... pleased to announce the publication of a new syndicated ... report covers the use of biologics for the treatment ... quarterly series, focuses on current and future use of ... of the key brands, barriers to broader usage, sales ...
... Nov. 2, 2010 Cypin Production, a leader in ... and China, is pleased to announce the already-high interest ... Strategies and Partnership Models for R&D Success". ... at the Hub Cira Centre in Philadelphia, is being ...
Cached Medicine Technology:Rheumatoid Arthritis Patient Share of Actemra Projected to Exceed Patient Share of Cimzia and Simponi Among the Medicare Population 2Cypin Production Announces Launch of U.S./China BioPharma Conference: 2
(Date:5/20/2013)... Mombo from Comfort & Harmony ... US Lactation Consultant Association (USLCA) May 2nd – 5th. ... other health professionals. , The USLCA annual conference ... discover and learn about the latest trends in lactation. ... nursing pillows, which new mothers use to help support ...
(Date:5/20/2013)... 2013 Mirena IUD lawsuit ... litigation recently established in U.S. District Court, Southern District ... to court records, the litigation’s first Status Conference was ... Plaintiff’s leadership positions were discussed. So far, at ... District of New York, all of which allege that ...
(Date:5/20/2013)... Co-founder of Atlanta SEO company EverSpark Interactive, ... 5th International INVEST Domaining & Internet Marketing Conference in ... and independent individuals from around the world to discuss ... The 2013 conference will take place at the Mexico ... to 21. A networking city tour day is on ...
(Date:5/20/2013)... May 20, 2013 Nearly 20 percent of kidneys ... are refused for transplant due to factors ranging from ... units to the organ going too long without blood ... these organs could be "recycled" to help solve the ... Forest Baptist Medical Center and colleagues, reporting in the ...
(Date:5/20/2013)... 2013 Horizon NJ Health, New Jersey’s ... that it has earned a Commendable Accreditation status ... NJ Health is a wholly owned subsidiary of Horizon ... NCQA Health Plan Accreditation is a nationally recognized program ... health plans provide to their members. Health Plan Accreditation ...
Breaking Medicine News(10 mins):Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:EverSpark CEO to be Keynote Speaker at 5th International INVEST Domaining & Internet Marketing Conference in Mexico City 2Health News:Study suggests new source of kidneys for transplant 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 2Health News:Horizon NJ Health Awarded Commendable Accreditation by NCQA 3
... ,Kick Butts Day, at 11 a.m. in Kettering, ... leaders from Ohio will hold a press conference on,Wednesday, ... how tobacco,companies take advantage of the lack of government ... aimed at hooking kids and,preventing current smokers from quitting. ...
... MIAMI, March 31 According to the World ... blacks, but,many Latinos and a few elderly Whites ... total incurable Glaucoma-Blindness,("White-Canes"). Most lack the opportunity to ... them of all their sight. Dr. Robert,Welsh, a ...
... highlights research on Blue Cross ... care utilization, EAGAN, Minn., March 31 In ... Quarterly, Blue Cross and Blue,Shield of Minnesota (Blue Cross) ... percent fewer visits to the emergency room and,had an ...
... 17,000 people with coronary artery disease or diabetes , , ... ACE inhibitor drug was as effective in reducing deaths, ... patients as a newer and more expensive angiotensin-receptor blocker ... The study of more than 17,000 people with coronary ...
... (Baltimore, MD) On April 2, the Kennedy Krieger ... Awareness Month with the one-year anniversary of the Interactive ... Launched in April 2007 by the Kennedy Krieger Institute, ... of causes, treatments, and the search for a possible ...
... Those Living with Epilepsy, TITUSVILLE, N.J., March 31 ... It has the ability to relay our deepest feelings ... strokes. For people,with epilepsy, art can be a valuable ... serious neurological condition., The sixth annual Expressions of ...
Cached Medicine News:Health News:Ohio Faith Leaders Call on Sen. Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 2Health News:New Welsh 'Self-Test' to Cure Glaucoma, the Leading Cause of Preventable Blindness 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 2Health News:Blue Cross' Consumer-directed Health Plan - Options Blue - Members Not Sacrificing Health for the Sake of Saving Money 3Health News:ACE Inhibitor as Effective as More Expensive Blood Pressure Drug 2Health News:First national autism registry shows notable impact on autism research in opening year 2Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 2Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 3Health News:People with Epilepsy Encouraged to Submit Artwork as Part of National Expressions of Courage(R) Art Contest 4
Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....
Ahmed Glaucoma Valve....
... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...
... Goldmann standard automatic or manual kinetic ... white/white, blue/yellow or red/white stimuli/background colors. ... classic 4-2 threshold strategy. Examination with ... (including 30-2, 24-2, and 10-2). Gray-scale/ ...
Medicine Products: